Medicine and Dentistry
Psoriasis
100%
Patient
51%
Therapeutic Procedure
49%
Association
34%
Inpatient
25%
Biological Product
21%
Disease
18%
Psoriasis Vulgaris
17%
Atopic Dermatitis
15%
Combination Therapy
14%
Analysis
14%
Biological Therapy
14%
Skin
14%
Pustular Psoriasis
13%
Systemic Therapy
13%
Methotrexate
12%
Cohort Analysis
11%
Psoriasis Area and Severity Index
11%
Dermatology
10%
Psoriatic Arthritis
10%
Pustulosis Palmaris Et Plantaris
10%
Systematic Review
8%
COVID-19
8%
Anakinra
8%
Placebo
8%
Chemotherapeutic Agent
7%
Drug
7%
Meta-Analysis
7%
Adult
7%
Inflammatory Disorder
7%
Biological Marker
7%
Amaurosis
7%
Infection
7%
Cardiovascular Disease
6%
Acneiform Eruption
6%
Liver Fibrosis
6%
Dermatosis
6%
Health Care Cost
6%
Consensus
5%
Genome Wide Association Study
5%
Acne Vulgaris
5%
Adalimumab
5%
Gene
5%
Allele
5%
Ustekinumab
5%
Statistical Analysis
5%
Treatment Response
5%
Corticosteroid
5%
Child
5%
Depression
5%
Nursing and Health Professions
Psoriasis
76%
Patient
29%
Biological Product
24%
Dermatologist
22%
Biological Therapy
15%
Inpatient
15%
Ustekinumab
14%
Confidence Interval
13%
Cohort Analysis
13%
Psoriasis Area and Severity Index
11%
Combination Therapy
11%
Methotrexate
10%
Drug
9%
Adalimumab
9%
Diseases
9%
Psoriatic Arthritis
9%
Systemic Therapy
9%
Placebo
8%
Infection
7%
Etanercept
7%
Prospective Cohort Study
6%
Cardiovascular Disease
6%
Adult
6%
Survival
6%
Systematic Review
6%
Screening
6%
Atopic Dermatitis
6%
Analysis
6%
Pustulosis palmoplantaris
5%
Hazard Ratio
5%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
84%
Biological Product
36%
Drug
21%
Adalimumab
19%
Cohort Study
19%
Methotrexate
18%
Atopic Dermatitis
13%
Ustekinumab
12%
Etanercept
9%
Infection
9%
Antibody
8%
Liver Fibrosis
8%
Prospective Cohort Study
7%
Psoriasis Vulgaris
6%
Inflammatory Disease
6%
Blindness
6%
Diseases
6%
Survival
6%
Adverse Event
6%
Pharmacogenetics
6%
Placebo
5%
Pustulosis palmoplantaris
5%
Tacrolimus
5%